

BCMA/TNFRSF17 Protein, Human, Recombinant (hFc & Avi), Biotinylated

General Information

Synonyms:	CD269;TNFRSF13A;BCMA;tumor necrosis factor receptor superfamily member 17;BCM
Protein Construction:	A DNA sequence encoding the human TNFRSF17 (NP_001183.2)(Met1-Ala54) was expressed with a c-terminal AVI tagged Fc region of human IgG1 at the C-terminus (Fc-AVI). The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Met 1
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q02223
Molecular Weight:	27.80 kDa (predicted); 41.44 kDa (reducing conditions)

QC Testing

Biological Activity:	Immobilized Recombinant Human BlyS / TNFSF13B / BAFF Protein (Fc Tag) at 2µg/mL (100µL/well) can bind Recombinant Human BCMA Protein (ECD, Fc & AVI Tag), Biotinylated , the EC50 is 0.8-2.5 ng/mL.
Purity:	≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in

mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Reference

Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. *Blood*. 103 (2): 689-94.

O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. *J Exp Med*. 199 (1): 91-8.

Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. *Curr Opin Immunol*. 18(3): 265-70.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481